Ubs Group Ag Aligos Therapeutics, Inc. Transaction History

Ubs Group Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.35 - $1.07 $3,662 - $11,195	-10,463 Reduced 96.66%	362 $0
Q1 2024 May 13, 2024	BUY	$0.64 - $1.13 $6,928 - $12,232	10,825 New	10,825 $10,000
Q3 2023 Nov 09, 2023	BUY	$0.71 - $1.06 $3,776 - $5,638	5,319 Added 4707.08%	5,432 $4,000
Q2 2023 Aug 11, 2023	SELL	$0.89 - $1.36 $1,972 - $3,013	-2,216 Reduced 95.15%	113 $0
Q1 2023 May 12, 2023	BUY	$0.87 - $2.11 $2,026 - $4,914	2,329 New	2,329 $2,000
Q1 2022 May 16, 2022	SELL	$2.08 - $12.2 $15,726 - $92,244	-7,561 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$11.48 - $17.69 $78,442 - $120,875	6,833 Added 938.6%	7,561 $90,000
Q3 2021 Nov 15, 2021	BUY	$14.57 - $17.72 $5,492 - $6,680	377 Added 107.41%	728 $11,000
Q2 2021 Aug 13, 2021	SELL	$20.3 - $33.6 $66,563 - $110,174	-3,279 Reduced 90.33%	351 $7,000
Q1 2021 May 12, 2021	BUY	$19.1 - $34.94 $37,569 - $68,726	1,967 Added 118.28%	3,630 $83,000
Q4 2020 Feb 11, 2021	BUY	$13.2 - $32.74 $21,951 - $54,446	1,663 New	1,663 $46,000

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.3B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.